Steroid implant for macular oedema

Ozurdex is an intravitreal implant containing 700 micograms of dexamethasone. It is indicated for the treatment of macular oedema following either branch retinal vein occlusion or central retinal vein occlusion. Treatment must be administered by an ophthalmologist.

Researchers tested Ozurdex in two double-blind, randomised trials in a total of 1267 patients. At 90 days after a single injection, the proportion of patients who had responded was significantly greater in the Ozurdex group than in the sham treatment group (21.8% vs 13.1%, p<0.001). Response was defined as an improvement of 15 letters or more in best corrected visual acuity.

Corticosteroids such as dexamethasone suppress the production of vascular endothelial growth factor, a cytokine that is involved in the development of macular oedema.

View Ozurdex drug record

Further information: Allergan

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases